Trading Halt
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Nexsen Limited has requested a trading halt for its securities pending an announcement regarding its RAPID-GBS clinical study update. The halt will remain in effect until the earlier of the announcement being made or the commencement of normal trading on a specified date. This request has been authorized by the company's board of directors.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/trading-halt-1594
Earlier from Nexsen
- Director Interest Notices re Performance Rights
- Notification regarding unquoted securities - NXN
- Annual Report - FY 2026
- Corporate Governance Statement and Appendix 4G
- Quarterly Report - Q4 FY26
Later from Nexsen
- Clear pathway defined to optimise StrepSure
- Suspension from Quotation
- Proposed FlashDx joint venture builds on CE-marked GBS test
- Reinstatement to Quotation
- Professor Shekhar Kumta appointed Executive Director
Follow Nexsen into a list and get an email when it puts out news.
Follow Nexsen